ASCO 2023 – China’s Dizal claims broad coverage with a super-Tagrisso
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
ASCO 2023 – Morpheus spurs Roche to take the red pill
After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.
ASCO 2023 – Merck’s Kelun deal gets its first validation
Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.
ASCO 2023 – Servier’s Indigo win comes with liver tox
Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.
ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
ASCO 2023 – ovarian cancer could provide a role for immuno-oncology at last
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.
ASCO 2023 – Bristol’s Commands data look good for Geron
The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.
ASCO 2023 – in Lag3 Regeneron could beat Bristol Myers Squibb
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
